An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

He, Qianjun; Zhang, Jiamin; Chen, Feng; Guo, Limin; Zhu, Ziyan; Shi, Jianlin

doi:10.1016/j.biomaterials.2010.07.008

Cited by 115 publications

(82 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positively charged DOX can be easily adsorbed onto the negatively charged surface, mainly the inner pore surface of MSNs, and the hydrogen bonding between the OH groups on the MSN surface and the -OH groups in DOX molecules will further promote the DOX loading. 27 So MSNs can load more DOX than CA4, while more CA4 can be loaded in DC@MSNs than in C@MSNs due to CA4 electrostatic interaction with the positively charged DOX. Figure 3B shows the drug release profiles (release amount and concentration) in a constant release medium within an interval of 50 hours.…”

mentioning

confidence: 96%

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Li¹,

Wu²,

Pan³

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

To overcome the drawback of drug non-selectivity in traditional chemotherapy, the construction of multifunctional targeting drug delivery systems is one of the most effective and prevailing approaches. The intratumoral anti-angiogenesis and the tumor cell-killing are two basic approaches in fighting tumors. Herein we report a novel tumor vascular-targeting multidrug delivery system using mesoporous silica nanoparticles as carrier to co-load an antiangiogenic agent (combretastatin A4) and a chemotherapeutic drug (doxorubicin) and conjugate with targeting molecules (iRGD peptide) for combined anti-angiogenesis and chemotherapy. Such a dual-loaded drug delivery system is capable of delivering the two agents at tumor vasculature and then within tumors through a differentiated drug release strategy, which consequently results in greatly improved antitumor efficacy at a very low doxorubicin dose of 1.5 mg/kg. The fast release of the antiangiogenic agent at tumor vasculatures led to the disruption of vascular structure and had a synergetic effect with the chemotherapeutic drug slowly released in the following delivery of chemotherapeutic drug into tumors.

show abstract

mentioning

confidence: 96%

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Li¹,

Wu²,

Pan³

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 On the other hand, the pores of the MSN and F127-OMSN are already filled with PBS, which significantly decreases the absorption capacity of particles and results in the observed anticoagulant behaviour of the particles. 20,21 Cargo loading and release studies were performed using a cancer drug, doxorubicin (DOX). We calculated a DOX loading capacity of 15.3 mg mg À1 for MSN.…”

mentioning

confidence: 99%

Pluronic polymer capped biocompatible mesoporous silica nanocarriers

et al. 2013

View full text Add to dashboard Cite

A facile self-assembly method is described to prepare PEGylated silica nanocarriers using hydrophobic mesoporous silica nanoparticles and a pluronic F127 polymer. Pluronic capped nanocarriers revealed excellent dispersibility in biological media with cyto-and blood compatibilities.The high surface area and pore volume, good chemical stability and ease of surface functionalization of mesoporous silica nanoparticles (MSNs) make them promising materials for biological applications as drug carriers and theranostic agents.1,2 In addition silica based materials are generally accepted as biocompatible materials by the U.S. Food and Drug Administration (FDA). However, recent studies demonstrated their potential in vitro and in vivo toxicity, especially when their size is reduced to the nano scale. 3,4 Although the toxicity of silica based nanomaterials depends on several factors including particle size, shape, surface chemistry and porosity, [5][6][7] there is a general consensus that chemical structure of the surface is the predominant factor which determines the interactions with biological systems. 8 The surface of bare silica is covered with negatively charged silanol groups, which can electrostatically interact with positively charged tetraalkylammonium moieties of the cell membrane and can lead to cytotoxicity by membranolysis or inhibition of cellular respiration. 8,9 Also, rapid aggregation of silica based nanoparticles in biological media can result in mechanical obstruction in the capillary vessels of several vital organs, leading to organ failure and even death. 10,11 Therefore, replacing the surface silanol groups with biocompatible molecules is essential to improve the biocompatibility of MSNs. Among numerous polymeric or organosilane surface modification ligands, polyethylene glycol (PEG) is the mostly used one due to its well established biocompatibility, hydrophilicity, and antifouling properties.12 However, the PEGylation process has some limitations;(i) it mostly requires tedious organic synthesis and surface modification 13 and (ii) pores of MSNs may be closed by the long PEG polymer chains, which can hinder the drug loading process. To overcome these limitations, here we report a facile self-assembly method using octyl modified hydrophobic MSNs and an amphiphilic block copolymer (F127). F127, a FDA approved biocompatible pluronic polymer, contains two hydrophilic PEG blocks and a hydrophobic polypropylene oxide (PPO) between the two PEG blocks. 14 When the powder of hydrophobic MSNs is added into the F127 solution they are easily transferred into water by selfassembly of F127 molecules onto the MSN surface through the hydrophobic interaction between the PPO block of F127 and surface octyl groups of the MSNs (Scheme 1). In addition, cargo loaded and PEGylated MSNs can be simply prepared by loading the hydrophobic MSNs before the F127 capping process. The F127 capped particles are dispersible in both water and phosphate buffered saline (PBS), whereas uncapped MSNs are easily aggregated and precipitated...

show abstract

“…11 Apart from anti-inflammation, anticoagulation, and antioxidation, Sal B has also shown obvious anticancer activity in a variety of cancer cell lines, including prostate, breast, liver, and head and neck squamous cell cancers. [12][13][14] Curcumin (Cur) is diferuloylmethane or 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hepadiene-3,5-dione, and has presented a comprehensive array of pharmacological properties, such as anti-inflammatory, antioxidant, anticancer, antimicrobial, antiparasitic, antitumor, antiangiogenic, and antimutagenic effects.…”

Section: Ding Et Almentioning

confidence: 99%

Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO<sub>2</sub>; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO<sub>2</sub> nanoparticles

Ding¹,

Li²,

Huang³

et al. 2016

IJN

View full text Add to dashboard Cite

An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

Cited by 115 publications

References 46 publications

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Pluronic polymer capped biocompatible mesoporous silica nanocarriers

Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO<sub>2</sub>; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO<sub>2</sub> nanoparticles

Contact Info

Product

Resources

About

An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles

Cited by 115 publications

References 46 publications

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor

Pluronic polymer capped biocompatible mesoporous silica nanocarriers

Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO<sub>2</sub>; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO<sub>2</sub>&nbsp;nanoparticles

Contact Info

Product

Resources

About

Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO<sub>2</sub>; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO<sub>2</sub> nanoparticles